Management of early-stage Hodgkin lymphoma /

Key Evidence for Recommendation 5 The evidence supporting this recommendation comes from one of the comparisons that the members of the Working Group identified as relevant: “PET versus no PET for tailoring the therapeutic strategy,” and includes the EORTC H10, H10F, and H10U studies [1] (see Tables 1E and 2E). [...] The members of the Working Group rated the quality of the evidence of the EORTC H10 [1] trial as moderate because the primary end-point, short-term PFS, is a surrogate for long-term OS. [...] The results of the EORTC H10 and of the RAPID trials point in the same direction. [...] The evidence in support of this recommendation includes patients of all ages representative of the target population, with favourable and unfavourable prognostic profiles, therefore the members of the Working Group considered this evidence generalizable to the entire target population. [...] The evolution of the evidence base has challenged the use of radiotherapy in the field of early-stage Hodgkin lymphoma (HL).